.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Angeles Alvarez Secord, MD, MHSc

Articles

Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

September 30th 2024

Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.

Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

September 30th 2024

Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.